GuidelineZeitschrift fur Rheumatologie2025
[Management of pulmonary and cardiovascular comorbidities in rheumatological diseases].
Guideline in Zeitschrift fur Rheumatologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary, renal and cardiovascular diseases as well as osteoporosis, must always be considered in the treatment of patients with inflammatory rheumatic diseases. Regardless of whether they are an organ manifestation of the underlying rheumatic disease, a medication side effect or a comorbidity, these diseases have a decisive influence on morbidity, mortality and the treatment decisions. This article is part 1 of a CME article containing information on current diagnostic and therapeutic recommendations for pulmonary and cardiovascular comorbidities. The newest American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) guidelines on cardiovascular manifestations are discussed and the guideline recommendations as well as insights into current therapeutic studies on the diagnostics and treatment of frequent pulmonary comorbidities in inflammatory rheumatic diseases are presented.
Indexed as
Identifiers
40736566What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.